Antonietta Bartoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antonietta Bartoli has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Piero Antonio Salvadori
CNR Institute of Clinical Physiology
3 shared publications - Silvia Burchielli
Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy
3 shared publications - Cinzia Talamonti
Dep. of Experimental and Biomedical Clinical Science,University of Florence,Florence,Italy; Istituto Nazionale di Fisica Nucleare, Sezione di Firenze,Florence,Italy, Italy
2 shared publications - Luca Menichetti
Institute of Clinical Physiology National Research Council Pisa Italy
2 shared publications - Maria Angela Guzzardi
Institute of Clinical Physiology, National Research Council (CNR), 56124 Pisa, Italy
2 shared publications - Patricia Iozzo
Institute of Clinical Physiology, National Research Council (CNR), via Moruzzi 1, Pisa, 56124, Italy.
2 shared publications
Latest Publications
- 6 September 2021
- Published by Springer Nature in International Journal of Obesity
- Vol. 46 (1) , 50-58
Leptin resistance before and after obesity: evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages
Background Leptin resistance occurs in obese patients, but its independent contribution to adiposity and the accompanying metabolic diseases, i.e., diabetes, liver steatosis, and steatohepatitis, remains to be established. This study was conducted in an extreme model of leptin resistance to investigate mechanisms initiating diabetes, fat expansion, liver steatosis, and inflammatory disease, focusing on the involvement of glucose intolerance and organ-specific glucose uptake in brown and subcutaneous adipose tissues (BAT, SAT) and in the liver. Methods We studied preobese and adult Zucker rats (fa/fa, fa/+ ) during fasting or glucose loading to assess glucose tolerance. Relevant pancreatic and intestinal hormonal levels were measured by Milliplex. Imaging of 18F-fluorodeoxyglucose by positron emission tomography was used to quantify glucose uptake in SAT, BAT, and liver, and evaluate its relationship with adipocyte size and biopsy-proven nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Results Preobese fa/fa pups showed impaired glucose tolerance, adipocyte enlargement, hepatic microsteatosis, and lobular inflammation, with elevated hepatic post-glucose load glucose uptake and production. Adult fa/fa rats had more severe glucose intolerance, fasting hyperglycemia, hormonal abnormalities, elevated glucose uptake in SAT and BAT, and more markedly in the liver, together with macrosteatosis, and highly prevalent hepatic inflammation. Organ glucose uptake was proportional to the degree of fat accumulation and tissue inflammation and was able to dissect healthy from NAFLD and NAFLD/NASH livers. Most severe NASH livers showed a decline in glucose uptake and liver enzymes. Conclusions In fa/fa Zucker rats, leptin resistance leads to glucose intolerance, mainly due to hepatic glucose overproduction, preceding obesity, and explaining pancreatic and intestinal hormonal changes and fat accumulation in adipocytes and hepatocytes. Our data support the involvement of liver glucose uptake in the pathogenesis of liver inflammatory disease. Its potential as more generalized biomarker or diagnostic approach remains to be established outside of our leptin-receptor-deficient rat model.
- 6 September 2021
- Published by Springer Nature in International Journal of Obesity
- Vol. 46 (1) , 50-58
Leptin resistance before and after obesity: evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages
Background Leptin resistance occurs in obese patients, but its independent contribution to adiposity and the accompanying metabolic diseases, i.e., diabetes, liver steatosis, and steatohepatitis, remains to be established. This study was conducted in an extreme model of leptin resistance to investigate mechanisms initiating diabetes, fat expansion, liver steatosis, and inflammatory disease, focusing on the involvement of glucose intolerance and organ-specific glucose uptake in brown and subcutaneous adipose tissues (BAT, SAT) and in the liver. Methods We studied preobese and adult Zucker rats (fa/fa, fa/+ ) during fasting or glucose loading to assess glucose tolerance. Relevant pancreatic and intestinal hormonal levels were measured by Milliplex. Imaging of 18F-fluorodeoxyglucose by positron emission tomography was used to quantify glucose uptake in SAT, BAT, and liver, and evaluate its relationship with adipocyte size and biopsy-proven nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Results Preobese fa/fa pups showed impaired glucose tolerance, adipocyte enlargement, hepatic microsteatosis, and lobular inflammation, with elevated hepatic post-glucose load glucose uptake and production. Adult fa/fa rats had more severe glucose intolerance, fasting hyperglycemia, hormonal abnormalities, elevated glucose uptake in SAT and BAT, and more markedly in the liver, together with macrosteatosis, and highly prevalent hepatic inflammation. Organ glucose uptake was proportional to the degree of fat accumulation and tissue inflammation and was able to dissect healthy from NAFLD and NAFLD/NASH livers. Most severe NASH livers showed a decline in glucose uptake and liver enzymes. Conclusions In fa/fa Zucker rats, leptin resistance leads to glucose intolerance, mainly due to hepatic glucose overproduction, preceding obesity, and explaining pancreatic and intestinal hormonal changes and fat accumulation in adipocytes and hepatocytes. Our data support the involvement of liver glucose uptake in the pathogenesis of liver inflammatory disease. Its potential as more generalized biomarker or diagnostic approach remains to be established outside of our leptin-receptor-deficient rat model.
- 1 December 2018
- Published by Elsevier in Physica Medica
- Vol. 56, 191-192
213. Pre-treatment verification of stereotactic plans using a bi-dimensional diamond detector
- 1 December 2018
- Published by Elsevier in Physica Medica
- Vol. 56, 191-192
213. Pre-treatment verification of stereotactic plans using a bi-dimensional diamond detector
- Open Access
- 10 March 2017
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 38 (3) , 447-455
Elevated glycemia and brain glucose utilization predict BDNF lowering since early life
Obesity and diabetes associate with neurodegeneration. Brain glucose and BDNF are fundamental in perinatal development. BDNF is related to brain health, food intake and glucose metabolism. We characterized the relationship between glycemia and/or brain glucose utilization (by 18FDG-PET during fasting and glucose loading), obesity and BDNF in 4-weeks old (pre-obese) and 12-weeks old (obese) Zucker fa/fa rats, and their age-matched fa/+ controls. In 75 human infants, we assessed cord blood BDNF and glucose levels, appetite regulating hormones, body weight and maternal factors. Young and adult fa/fa rats showed glucose intolerance and brain hyper-utilization compared to controls. Glycemia and age were positively related to brain glucose utilization, and were negative predictors of BDNF levels. In humans, fetal glycemia was dependent on maternal glycemia at term, and negatively predicted BDNF levels. Leptin levels were associated with higher body weight and lower BDNF levels. Glucose intolerance and elevated brain glucose utilization already occur in young, pre-obese rats, suggesting that they precede obesity onset in Zucker fatty rats. Glycemic elevation and brain glucose overexposure predict circulating BDNF deficiency since perinatal and early life. Future studies should evaluate whether the control of maternal and fetal glycemia during late intrauterine development can prevent these unfavorable interactions.
- 10 March 2017
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 38 (3) , 447-455
Open AccessElevated glycemia and brain glucose utilization predict BDNF lowering since early life
Obesity and diabetes associate with neurodegeneration. Brain glucose and BDNF are fundamental in perinatal development. BDNF is related to brain health, food intake and glucose metabolism. We characterized the relationship between glycemia and/or brain glucose utilization (by 18FDG-PET during fasting and glucose loading), obesity and BDNF in 4-weeks old (pre-obese) and 12-weeks old (obese) Zucker fa/fa rats, and their age-matched fa/+ controls. In 75 human infants, we assessed cord blood BDNF and glucose levels, appetite regulating hormones, body weight and maternal factors. Young and adult fa/fa rats showed glucose intolerance and brain hyper-utilization compared to controls. Glycemia and age were positively related to brain glucose utilization, and were negative predictors of BDNF levels. In humans, fetal glycemia was dependent on maternal glycemia at term, and negatively predicted BDNF levels. Leptin levels were associated with higher body weight and lower BDNF levels. Glucose intolerance and elevated brain glucose utilization already occur in young, pre-obese rats, suggesting that they precede obesity onset in Zucker fatty rats. Glycemic elevation and brain glucose overexposure predict circulating BDNF deficiency since perinatal and early life. Future studies should evaluate whether the control of maternal and fetal glycemia during late intrauterine development can prevent these unfavorable interactions.
- 1 September 2016
- Published by Elsevier in Physica Medica
- Vol. 32, 215
Small field relative dosimetry using a silicon diode of new generation
- 1 September 2016
- Published by Elsevier in Physica Medica
- Vol. 32, 215
Small field relative dosimetry using a silicon diode of new generation
- 27 May 2016
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 18 (6) , 916-923
Synthesis and In Vivo Imaging of N-(3-[11C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein
Purpose The plasma membrane P-glycoprotein (Pgp) is an efflux transporter involved in multidrug resistance and in the onset of neurodegenerative disease. Its function and most mechanisms of action are still under investigation. We developed a C-11-labeled 2-arylethylphenylamine-([11C]AEPH) derivative for positron emission tomography (PET), as a novel probe to better understand the activity and the function of Pgp in vivo. Procedures The synthetic procedure and the quality control of the selected lead compound, [11C]AEPH-1, were set up and optimized. The biodistribution and the dynamic extraction in target organs of [11C]AEPH-1 were studied in vivo by PET in healthy rats at baseline and after pre-treatment with a Pgp inhibitor (tariquidar). Results In vivo dynamic imaging was consistent with the results of ex vivo extraction on explanted organs. An adequate stability for in vivo studies, as well as a high activity of [11C]AEPH-1 in intestine and barrier tissues, has been demonstrated. Results of the blockade study showed a decrease of uptake after the pre-treatment, indicating a behavior attributable to a Pgp ligand. Conclusions The suitable pharmacokinetics and the specificity tested in the pre-treated animals have indicated the potentiality of this AEPH derivative to act as Pgp ligand, providing new opportunities for further studies on expression and function of this important efflux transporter in the fields of neurology and oncology.
- 27 May 2016
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 18 (6) , 916-923
Synthesis and In Vivo Imaging of N-(3-[11C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein
Purpose The plasma membrane P-glycoprotein (Pgp) is an efflux transporter involved in multidrug resistance and in the onset of neurodegenerative disease. Its function and most mechanisms of action are still under investigation. We developed a C-11-labeled 2-arylethylphenylamine-([11C]AEPH) derivative for positron emission tomography (PET), as a novel probe to better understand the activity and the function of Pgp in vivo. Procedures The synthetic procedure and the quality control of the selected lead compound, [11C]AEPH-1, were set up and optimized. The biodistribution and the dynamic extraction in target organs of [11C]AEPH-1 were studied in vivo by PET in healthy rats at baseline and after pre-treatment with a Pgp inhibitor (tariquidar). Results In vivo dynamic imaging was consistent with the results of ex vivo extraction on explanted organs. An adequate stability for in vivo studies, as well as a high activity of [11C]AEPH-1 in intestine and barrier tissues, has been demonstrated. Results of the blockade study showed a decrease of uptake after the pre-treatment, indicating a behavior attributable to a Pgp ligand. Conclusions The suitable pharmacokinetics and the specificity tested in the pre-treated animals have indicated the potentiality of this AEPH derivative to act as Pgp ligand, providing new opportunities for further studies on expression and function of this important efflux transporter in the fields of neurology and oncology.
- 1 May 2016
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (5) , 309-317
Toward PET imaging of A2B adenosine receptors: a carbon-11 labeled triazinobenzimidazole tracer
- 1 May 2016
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (5) , 309-317
Toward PET imaging of A2B adenosine receptors: a carbon-11 labeled triazinobenzimidazole tracer
- 1 January 2007
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 5 (10823654) , 3408-3413
Simultaneous PET/SPECT imaging with the small animal scanner YAP-(S)PET
To exploit the YAP-(S)PET II scanner intrinsic capability of both PET and SPECT imaging, we have implemented the simultaneous PET/SPECT dual imaging modality. Two opposing heads, equipped with collimator and set in anticoincidence, independently acquire single events (SPECT mode), the other pair of heads detects coincidence events (PET mode). During the simultaneous PET/SPECT acquisition, both a high energy (PET) and a low energy (SPECT) radiotracer are placed inside the Field of View (FOV). Since the thickness of the collimator (2 cm) is optimized to stop only low energy photons, the down-scatter from 511 keV photons seriously affects the single photon acquisition. It is therefore necessary to perform a subtraction procedure before SPECT data analysis. The subtraction procedure is based on a multi-energy window method. The background underneath the 99mTc photo-peak region can then be approximated as a fraction (f) of the counts measured in an energy window close to the photo-peak but containing only Compton events. Good results were obtained for simultaneous imaging of two 5 mm syringes containing 99mTc and 18F with a SPECT/PET radiotracers ratio 10:1.
- 1 January 2007
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 5 (10823654) , 3408-3413
Simultaneous PET/SPECT imaging with the small animal scanner YAP-(S)PET
To exploit the YAP-(S)PET II scanner intrinsic capability of both PET and SPECT imaging, we have implemented the simultaneous PET/SPECT dual imaging modality. Two opposing heads, equipped with collimator and set in anticoincidence, independently acquire single events (SPECT mode), the other pair of heads detects coincidence events (PET mode). During the simultaneous PET/SPECT acquisition, both a high energy (PET) and a low energy (SPECT) radiotracer are placed inside the Field of View (FOV). Since the thickness of the collimator (2 cm) is optimized to stop only low energy photons, the down-scatter from 511 keV photons seriously affects the single photon acquisition. It is therefore necessary to perform a subtraction procedure before SPECT data analysis. The subtraction procedure is based on a multi-energy window method. The background underneath the 99mTc photo-peak region can then be approximated as a fraction (f) of the counts measured in an energy window close to the photo-peak but containing only Compton events. Good results were obtained for simultaneous imaging of two 5 mm syringes containing 99mTc and 18F with a SPECT/PET radiotracers ratio 10:1.
- 10 August 2005
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 6, 3831-3834
Mathematical-physical characterization of the response function of a clinical positron emission tomography
- 10 August 2005
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 6, 3831-3834
Mathematical-physical characterization of the response function of a clinical positron emission tomography